Has Gladstone McDowell, MD received payments from drug or device companies?

Yes. Drug and device makers reported $701,344 in general payments to Gladstone McDowell, MD across 1,366 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gladstone McDowell, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gladstone McDowell, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gladstone McDowell, MD

Interventional Pain Medicine · Columbus, OHNPI 1346296621

Payments from drug & device makers

$701,344in general payments, 2019–2025

Across 1,366 payments — averaging $513.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Tersera Therapeutics LLC$588K
Medtronic$42K
Nevro Corp.$38K
Flowonix Medical Incorporated$16K
Stimwave Technologies Incorporated$5K
Biotronik Inc.$5K
plus $8K from 37 others

$53,150in research payments, 2019–2025

Across 9 payments — averaging $5905.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Nevro Corp.$51K
Flowonix Medical Incorporated$2K

What the payments were for

Consulting fees$406,84062%
Speaking & faculty fees$129,18220%
Travel & lodging$103,21516%
Food & beverage$21,0373%
Education$290%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Tersera Therapeutics LLC	903	$587,941
Medtronic(2 entities)	64	$42,284
Nevro Corp.	71	$37,818
Flowonix Medical Incorporated	3	$15,561
Stimwave Technologies Incorporated	17	$5,475
Biotronik Inc.	29	$4,614
Boston Scientific	78	$1,674
Abbott	44	$1,514
Spinal Simplicity, LLC	14	$1,235
Collegium Pharmaceutical, Inc.	26	$481
AbbVie(2 entities)	26	$422
Vertos Medical, Inc.	4	$322
Scilex Pharmaceuticals Inc.	10	$179
Saluda Medical Americas, Inc.	1	$154
Spinefrontier, Inc.	2	$143
Pfizer	9	$137
Amgen(2 entities)	6	$108
Trevena, Inc.	1	$104
Biodelivery Sciences International, Inc.	7	$102
Nalu Medical, Inc.	4	$102
Vertiflex, Inc.	1	$98
SPR Therapeutics, Inc	2	$75
MDD US Operations, LLC	5	$75
Axonics, Inc.	4	$73
Teva Pharmaceuticals USA, Inc.	5	$67
CDC Medical LLC	1	$59
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$58
Vertex	1	$53
Biohaven Pharmaceutical Holding Company Ltd.	3	$51
IBSA Pharma Inc.	3	$47
Biohaven Pharmaceuticals, Inc.	3	$44
GRT US Holding, Inc.	2	$41
Bioventus LLC	1	$36
Supernus Pharmaceuticals, Inc.	2	$34
Zyla Life Sciences, Inc.	2	$28
Relievant Medsystems, Inc.	2	$23
Arbor Pharmaceuticals, Inc.	1	$20
Pacira Pharmaceuticals Incorporated	1	$20
Si-bone, Inc.	1	$20
Baudax Bio Inc.	1	$19
Lundbeck LLC	1	$16
Fidia Pharma USA Inc.	1	$12
Daiichi Sankyo Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PRIALT$570,675
Senza Spinal Cord Stimulation System$31,046
Prometra II$15,561
SYNCHROMED$7,765
QUZYTTIR$2,592
Omnia$1,512
HA MINUTEMAN G3-R$1,027
CFNS StimQ Peripheral Nerve StimulatorSystem$416
SCS FreedonSpinal Cord Stimulator$416
PROCLAIM$341
GENERAL - THERAPIES$237
SYNCHROMEDII$234
mild Device Kit$228
GENERAL PAIN MANAGEMENT$209
Evoke$154
Neuromodulation Dspsbls and Accs$142
Proclaim Family of SCS IPGs$139
InSpan$115
SacroFuse$115
NanoFuse Putty$115

How this compares

$701,344 in reported general payments places this provider in the 95th percentile of 67 interventional pain medicine providers in Ohio.

See all interventional pain medicine providers in Ohio →

Medicare billing

Part B allowed, 2024

$10,313

Medicare patients

Services billed

108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	18	$185
Tizanidine Hcl	53	$163
Topiramate	13	$117

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Columbus

David WalegaColumbus$75K
Jayesh VallabhColumbus$73K
Steven BhutraColumbus$13K
Amol SoinDayton$184K
Sara NashiCincinnati$140K
Humam AkbikFairfield$117K
Jaudat MahmoodKent$97K
Omar AliSpringfield$67K
Dustin ReynoldsWesterville$62K
Mark MalinowskiChillicothe$57K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →